Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
作者信息
Shiver Mallory B, Mahmoud Fade, Gao Ling
机构信息
University of Arkansas for Medical Sciences, Little Rock, AR
出版信息
N Engl J Med. 2015 Oct 15;373(16):1580-2. doi: 10.1056/NEJMc1507446.
Abstract
摘要
相似文献
1
Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.一名IV期默克尔细胞癌患者对idelalisib的反应。
N Engl J Med. 2015 Oct 15;373(16):1580-2. doi: 10.1056/NEJMc1507446.
2
More on Merkel-Cell Carcinoma.更多关于默克尔细胞癌的内容。
N Engl J Med. 2016 Feb 4;374(5):495. doi: 10.1056/NEJMc1514347.
3
More on Merkel-Cell Carcinoma.更多关于默克尔细胞癌的内容。
N Engl J Med. 2016 Feb 4;374(5):494-5. doi: 10.1056/NEJMc1514347.
4
Idelalisib for chronic lymphocytic leukemia.idelalisib用于治疗慢性淋巴细胞白血病。
Clin Adv Hematol Oncol. 2014 Dec;12(12):846-8.
5
Idelalisib has activity in mantle cell lymphoma.依鲁替尼在套细胞淋巴瘤中有活性。
Cancer Discov. 2014 May;4(5):OF8. doi: 10.1158/2159-8290.CD-RW2014-072. Epub 2014 Mar 27.
6
Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma.依鲁替尼通过 AKT/FoxO3a 促进肝癌细胞中的 Bim 依赖性细胞凋亡。
Cell Death Dis. 2018 Sep 17;9(10):935. doi: 10.1038/s41419-018-0960-8.
7
Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.血液系统癌症：idelalisib靶向B细胞恶性肿瘤患者的PI3Kδ
Nat Rev Clin Oncol. 2014 Apr;11(4):184-6. doi: 10.1038/nrclinonc.2014.42. Epub 2014 Mar 18.
8
Management of adverse events associated with idelalisib treatment: expert panel opinion.idelalisib治疗相关不良事件的管理：专家小组意见
Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19.
9
[Grave diarrhea associated with idelalisib administration].[与服用idelalisib相关的严重腹泻]
Farm Hosp. 2016 May 1;40(3):227-9. doi: 10.7399/fh.2016.40.3.10450.
10
Idelalisib: targeting PI3Kδ in B-cell malignancies.idelalisib：靶向B细胞恶性肿瘤中的PI3Kδ
Lancet Oncol. 2014 Mar;15(3):e108. doi: 10.1016/s1470-2045(14)70052-x.
引用本文的文献
1
Understanding Merkel Cell Carcinoma: Pathogenic Signaling, Extracellular Matrix Dynamics, and Novel Treatment Approaches.了解默克尔细胞癌：致病信号传导、细胞外基质动态变化及新的治疗方法。
Cancers (Basel). 2025 Apr 2;17(7):1212. doi: 10.3390/cancers17071212.
2
Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.推进 Merkel 细胞癌的治疗选择：肿瘤靶向治疗的综述。
Int J Mol Sci. 2024 Oct 15;25(20):11055. doi: 10.3390/ijms252011055.
3
Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities.非黑色素瘤皮肤癌的治疗方法：标准护理和新兴疗法。
Int J Mol Sci. 2024 Jun 27;25(13):7056. doi: 10.3390/ijms25137056.
4
Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities.单细胞剖析 Merkel 细胞癌异质性揭示转录组可塑性和治疗弱点。
Cell Rep Med. 2023 Jul 18;4(7):101101. doi: 10.1016/j.xcrm.2023.101101. Epub 2023 Jul 7.
5
Merkel Cell Carcinoma-Update on Diagnosis, Management and Future Perspectives.Merkel细胞癌——诊断、治疗及未来展望的最新进展
Cancers (Basel). 2022 Dec 23;15(1):103. doi: 10.3390/cancers15010103.
6
Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis.AK-01/LY3295668对极光激酶A的选择性抑制通过诱导MCC细胞周期停滞和凋亡来减弱MCC肿瘤生长。
Cancers (Basel). 2021 Jul 23;13(15):3708. doi: 10.3390/cancers13153708.
7
An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response.分析晚期 Merkel 细胞癌患者中靶向治疗的应用，并评估反应的基因组相关性。
Cancer Med. 2021 Sep;10(17):5889-5896. doi: 10.1002/cam4.4138. Epub 2021 Jul 16.
8
Merkel Cell Polyomavirus and Merkel Cell Carcinoma.默克尔细胞多瘤病毒与默克尔细胞癌
Cancers (Basel). 2020 Jul 3;12(7):1774. doi: 10.3390/cancers12071774.
9
Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.考潘立司他抑制 PI3K 对 Merkel 细胞癌细胞系和小鼠异种移植物发挥强大的抗肿瘤作用。
Sci Rep. 2020 Jun 1;10(1):8867. doi: 10.1038/s41598-020-65637-2.
10
A rare case of Merkel cell carcinoma with ovarian metastasis.1例罕见的伴有卵巢转移的默克尔细胞癌。
Gynecol Oncol Rep. 2019 Mar 20;28:76-78. doi: 10.1016/j.gore.2019.03.011. eCollection 2019 May.
本文引用的文献
1
A Proteomic Study of Human Merkel Cell Carcinoma.人类默克尔细胞癌的蛋白质组学研究
J Proteomics Bioinform. 2013 Nov 25;6:275-282. doi: 10.4172/jpb.1000291.
2
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.PI(3)K p110δ 的失活破坏了调节性 T 细胞介导的对癌症的免疫耐受。
Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11.
3
Idelalisib--a PI3Kδ inhibitor for B-cell cancers.idelalisib——一种用于治疗B细胞癌症的PI3Kδ抑制剂。
N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055.
4
Merkel Cell Carcinoma: Epidemiology, Target, and Therapy.默克尔细胞癌：流行病学、靶点与治疗
Curr Dermatol Rep. 2014 Jan 22;3(1):46-53. doi: 10.1007/s13671-014-0068-z. eCollection 2014.
5
Activation of PI3K signaling in Merkel cell carcinoma.Merkel 细胞癌中 PI3K 信号的激活。
Clin Cancer Res. 2012 Mar 1;18(5):1227-36. doi: 10.1158/1078-0432.CCR-11-2308. Epub 2012 Jan 18.
Zotero 插件